Personalised cancer follow-up: risk stratification, needs assessment or both?
作者信息
Filleron T, Dalenc F, Kramar A
出版信息
Br J Cancer. 2012 Apr 24;106(9):1579-80. doi: 10.1038/bjc.2012.108.
Abstract
摘要
相似文献
1
Personalised cancer follow-up: risk stratification, needs assessment or both?个性化癌症随访：风险分层、需求评估还是两者兼顾？
Br J Cancer. 2012 Apr 24;106(9):1579-80. doi: 10.1038/bjc.2012.108.
2
Personalised cancer follow-up: risk stratification, needs assessment or both?个性化癌症随访：风险分层、需求评估还是两者兼顾？
Br J Cancer. 2012 Jan 3;106(1):1-5. doi: 10.1038/bjc.2011.535.
3
Establishing treatment optimisation as part of personalised medicine development.将治疗优化确立为个性化医疗发展的一部分。
Eur J Cancer. 2019 May;113:96-97. doi: 10.1016/j.ejca.2019.03.014. Epub 2019 Apr 15.
4
The Promise and the Hype of 'Personalised Medicine'.“个性化医疗”的前景与炒作
New Bioeth. 2017 Apr;23(1):13-20. doi: 10.1080/20502877.2017.1314886.
5
The next age of immunotherapy: optimisation, stratification and therapeutic synergies.免疫治疗的新纪元：优化、分层和治疗协同作用。
Br J Cancer. 2019 Jan;120(1):1-2. doi: 10.1038/s41416-018-0330-4. Epub 2018 Nov 9.
6
A new year and a bright hope for personalised medicine, but what about the quality of cancer patient care?新的一年，个性化医疗充满光明希望，但癌症患者的护理质量又如何呢？
Eur J Cancer Care (Engl). 2013 Jan;22(1):1-2. doi: 10.1111/ecc.12034.
7
Tailoring cancer therapy - validating basic science with the 'supertrial'.精准医疗——用“超级试验”验证基础科学。
Mol Oncol. 2009 Dec;3(5-6):389-91. doi: 10.1016/j.molonc.2009.08.001.
8
Personalised cancer care: promises and challenges of targeted therapy.个性化癌症护理：靶向治疗的前景与挑战
J R Soc Med. 2016 Mar;109(3):98-105. doi: 10.1177/0141076816631154. Epub 2016 Mar 1.
9
UK’s adopts systematic approach to personalised cancer medicine.英国采用系统方法推进个性化癌症医疗。
Mol Oncol. 2011 Jun;5(3):217-9. doi: 10.1016/j.molonc.2011.04.002.
10
Patient-reported outcomes and personalised cancer care.患者报告的结局与个性化癌症护理。
Med J Aust. 2021 May;214(9):406-408.e1. doi: 10.5694/mja2.50893. Epub 2020 Dec 13.
引用本文的文献
1
A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.用于个性化监测测试时间的信息价值框架。
Med Decis Making. 2022 May;42(4):474-486. doi: 10.1177/0272989X211049213. Epub 2021 Nov 7.
2
User experiences on implementation of patient reported outcome measures (PROMs)in a Haematological outpatient clinic.患者在血液科门诊实施患者报告结局量表（PROMs）方面的体验。
J Patient Rep Outcomes. 2020 Oct 28;4(1):87. doi: 10.1186/s41687-020-00256-z.
本文引用的文献
1
Personalised cancer follow-up: risk stratification, needs assessment or both?个性化癌症随访：风险分层、需求评估还是两者兼顾？
Br J Cancer. 2012 Jan 3;106(1):1-5. doi: 10.1038/bjc.2011.535.
2
Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: the FATSEIN study.辅助化疗前、中、后乳腺癌患者疲劳相关因素：FATSEIN 研究。
Contemp Clin Trials. 2011 Mar;32(2):244-9. doi: 10.1016/j.cct.2010.11.007. Epub 2010 Nov 13.
3
Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.皮肤黑色素瘤转移灶检测及后续检查的费用。
Melanoma Res. 2009 Feb;19(1):50-7. doi: 10.1097/CMR.0b013e32831bc41c.
4
Planning posttherapeutic oncology surveillance visits based on individual risk.根据个体风险规划肿瘤治疗后随访就诊。
Med Decis Making. 2009 Sep-Oct;29(5):570-9. doi: 10.1177/0272989X08327331. Epub 2009 Feb 9.
5
Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians.癌症治疗后护理的观点：对幸存者、护士和医生的定性研究。
J Clin Oncol. 2007 Jun 1;25(16):2270-3. doi: 10.1200/JCO.2006.10.0826.
6
Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO.通过对初始治疗后首次失败模式的研究优化随访时机。以非小细胞肺癌患者为例：欧洲放射肿瘤学会（ESTRO）REACT工作组的一项研究
Radiother Oncol. 2006 Jan;78(1):95-100. doi: 10.1016/j.radonc.2005.09.012. Epub 2005 Oct 26.
7
Methodology to predict a maximum follow-up period for breast cancer patients without significantly reducing the chance of detecting a local recurrence.在不显著降低检测局部复发几率的情况下预测乳腺癌患者最大随访期的方法。
Phys Med Biol. 2004 Mar 21;49(6):1079-83. doi: 10.1088/0031-9155/49/6/015.
8
Normal tissue effects: reporting and analysis.正常组织效应：报告与分析
Semin Radiat Oncol. 2003 Jul;13(3):189-202. doi: 10.1016/S1053-4296(03)00036-5.
9
A qualifier Q for the survival function to describe the prevalence of a transient condition.用于描述短暂状况患病率的生存函数的一个限定词Q。
Stat Med. 1991 Mar;10(3):413-21. doi: 10.1002/sim.4780100313.
Zotero 插件